Alembic Pharmaceuticals receives USFDA approval for Fingolimod Capsules ANDA EP News Bureau Apr 27, 2026 Approval for 0.5 mg capsules therapeutically equivalent to Novartis’ Gilenya; market size at US$ 145 million
Alembic Pharmaceuticals secures USFDA approval for Dapagliflozin Tablets ANDA EP News Bureau Apr 7, 2026 Approval grants eligibility for 180-day shared generic drug exclusivity
Alembic Pharmaceuticals receives USFDA approval for Efinaconazole Topical Solution, 10% EP News Bureau Feb 24, 2026 Product is therapeutically equivalent to Jublia; company holds 234 USFDA ANDA approvals
